1
Robert F Kaiko, Robert D Colucci: Opioid agonist/antagonist combinations. Euro Celtique, Davidson Davidson & Kappel, February 24, 2004: US06696066 (163 worldwide citation)

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is ana ...


2
Robert F Kaiko, Robert D Colucci: Opioid agonist/antagonist combinations. Euro Celtique, Davidson Davidson & Kappell, August 21, 2001: US06277384 (141 worldwide citation)

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is ana ...


3
Robert F Kaiko, Robert D Colucci: Opioid agonist/antagonist combinations. Euro Celtique, Davidson Davidson & Kappel, November 5, 2002: US06475494 (125 worldwide citation)

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is ana ...


4
Robert F Kaiko, Robert D Colucci: Opioid agonist / antagonist combinations. Purdue Pharma, Davidson Davidson & Kappel, February 6, 2007: US07172767 (99 worldwide citation)

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is ana ...


5
Robert F Kaiko, Robert D Colucci: Opioid agonist/antagonist combinations. Purdue Pharma, Davidson Davidson & Kappel, September 2, 2008: US07419686 (59 worldwide citation)

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is ana ...


6
Robert F Kaiko, Robert D Colucci: Opioid agonist/antagonist combinations. Purdue Pharma, Davidson Davidson & Kappel, July 6, 2010: US07749542 (37 worldwide citation)

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is ana ...


7
Robert F Kaiko, Robert D Colucci: Opioid agonist/antagonist combinations. Purdue Pharma, Davidson Davidson & Kappel, January 31, 2012: US08105631 (36 worldwide citation)

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is ana ...


8
Robert F Kaiko, Robert D Colucci: Opioid agonist/antagonist combinations. Purdue Pharma, Dechert, March 18, 2014: US08673355 (13 worldwide citation)

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is ana ...


9
Robert F Kaiko, Robert D Colucci: Opioid agonist/antagonist combinations. Purdue Pharma, Dechert, January 13, 2015: US08932630 (3 worldwide citation)

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is ana ...


10